A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT02539225 · COMPLETED
Trial details
- NCT number
- NCT02539225
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-05
- Primary completion
- 2017-10-25
- Enrollment
- 191
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.